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ABSTRACT
Cancer cells are frequently exposed to physiological stress conditions such 
as hypoxia and nutrient limitation. Escape from stress-induced apoptosis is one of 
the mechanisms used by malignant cells to survive unfavorable conditions. B-cell 
Translocation Gene 1 (BTG1) is a tumor suppressor that is frequently deleted in acute 
lymphoblastic leukemia and recurrently mutated in diffuse large B cell lymphoma. 
Moreover, low BTG1 expression levels have been linked to poor outcome in several 
solid tumors. How loss of BTG1 function contributes to tumor progression is not 
well understood. Here, using Btg1 knockout mice, we demonstrate that loss of 
Btg1 provides a survival advantage to primary mouse embryonic fibroblasts (MEFs) 
under stress conditions. This pro-survival effect involves regulation of Activating 
Transcription Factor 4 (ATF4), a key mediator of cellular stress responses. We show 
that BTG1 interacts with ATF4 and positively modulates its activity by recruiting the 
protein arginine methyl transferase PRMT1 to methylate ATF4 on arginine residue 
239. We further extend these findings to B-cell progenitors, by showing that loss of 
Btg1 expression enhances stress adaptation of mouse bone marrow-derived B cell 
progenitors. In conclusion, we have identified the BTG1/PRMT1 complex as a new 
modifier of ATF4 mediated stress responses.
INTRODUCTION
During cancer progression, tumor cells are exposed 
to physiological stresses, such as hypoxia and nutrient 
limitation, either as a result of aberrant proliferation or 
chemotherapy intervention [1]. Depending on the cell 
type as well as the intensity or duration of stress, tumor 
cells will either employ survival mechanisms or initiate 
programmed cell death. Activating Transcription Factor 4 
(ATF4) is a master regulator of the stress response 
pathway that is activated upon micro-environmental 
stresses including ER stress, amino acid limitation, 
fluctuations in nutrient availability, hypoxia and 
oxidative stress [2–8]. In general, stressed cells turn on 
the amino acid response (AAR) (triggered by amino 
acid limitation) or the unfolded protein response (UPR) 
(triggered by endoplasmic reticulum (ER) stress) by 
activating GCN2 or PERK protein kinases, respectively. 
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The phosphorylation events mediated by these kinases 
repress global protein synthesis but paradoxically increase 
the translation of a subset of mRNAs, including that of 
ATF4 [2, 3, 9]. This member of the basic-region leucine 
zipper (bZIP) transcription factor family both directly 
and indirectly promotes the expression of hundreds of 
genes involved in metabolism, protein synthesis and 
nutrient homeostasis. ATF4 targets also include genes 
that promote apoptosis (e.g., DDIT3, TRB3) [2, 10], 
which allows ATF4 to establish a tight balance between 
salvage and cell death, depending on the ability of the 
cells to adapt to environmental challenges. Consequently, 
ATF4-mediated stress responses govern metabolic and 
oxidative adaptation in various cell types such as neurons, 
osteoblasts, hepatocytes and hematopoietic stem cells 
[6, 11–13]. Moreover, this pathway is deregulated in a 
variety of cancers, including fibrosarcoma, neuroblastoma, 
multiple myeloma and breast cancer, which allows cancer 
cells to sustain growth under unfavorable circumstances 
[14–17].
The B-cell Translocation Gene 1 (BTG1) belongs 
to the BTG/Tob anti-proliferation gene family [18, 19]. 
The protein product expressed by the BTG1 gene is 
broadly expressed and regulates various biological 
and cellular processes including cell cycle regulation, 
control of proliferation and differentiation, induction of 
apoptosis, transcriptional activation, and regulation of 
mRNA stability [19–22]. BTG1 has no intrinsic catalytic 
activity but rather acts as an adaptor protein for other 
regulatory molecules. For instance, BTG1 was shown to 
act as a transcriptional co-regulator by interacting with and 
recruiting protein arginine methyltransferase 1 (PRMT1) 
to transcription factor complexes [23]. We and others 
have shown that BTG1 is affected by monoallelic deletion 
in about 9% of childhood pre-B acute lymphoblastic 
leukemia (B-ALL) cases [24, 25], and that existing or 
novel BTG1 copy number aberrations can be detected at 
relapse [26, 27]. In addition, BTG1 is among recurrently 
mutated genes detected in B-cell lymphoma samples 
[28, 29]. Furthermore, low BTG1 mRNA expression 
is associated with poor outcome or tumor metastasis in 
several solid tumors [30–35]. How tumor cells benefit 
from loss of BTG1 function remains to be elucidated.
Given the fact that the expression of BTG1, 
and its closest family member BTG2, are increased 
by a wide range of stress-inducing stimuli, such as 
chemotherapeutic compounds and genotoxic agents 
[36, 37], we hypothesized that both proteins may act to 
modulate cellular stress response pathways. In this report, 
we investigated the involvement of BTG1 and BTG2 in 
regulating ATF4, a critical regulator of the integrated stress 
response both in normal and cancer cells [8, 9, 14, 38, 39]. 
We demonstrate that loss of BTG1, but not BTG2, protects 
cells from cellular stress-mediated apoptosis by reducing 
PRMT1-mediated arginine methylation of ATF4.
RESULTS
Loss of BTG1 promotes survival in response to 
cellular stress
BTG/TOB family members have been implicated in 
the inhibition of cell growth and the induction of apoptosis 
in a variety of model systems [19, 40–45]. Here, we 
applied a range of compounds to induce ATF4-mediated 
cellular stress responses (drug-induced ER stress, amino 
acid limitation and nutrient depletion) and found the Btg1 
mRNA to be upregulated in mouse embryonic fibroblasts 
(MEFs) in response to these stressors (Figure 1A). In 
contrast, the Btg2 transcript remained unaffected under 
these conditions. To establish a role for BTG1 in the ATF4 
stress response pathway, we challenged primary MEFs 
deficient for Btg1 or Btg2 with amino acid and nutrient 
limitation as well as ER stress-inducing compounds. We 
quantified cell viability before and after stress treatment 
using an MTT-based viability assay, and the percentage 
of cell survival was calculated relative to untreated cells 
(set to 100%). There was no significant difference in 
the growth properties between cells derived from each 
genotype under normal conditions (data not shown). We 
observed that while Btg2 knockout cells cope with stress 
similarly to wild-type (WT) cells, loss of Btg1 provides 
a significant survival benefit (Figure 1B). By measuring 
the amount of lactate dehydrogenase (LDH) released into 
medium, as a measure of cell death, we confirmed that 
Btg1 knockout cells are more resistant to cellular stress 
in comparison to WT cells (Supplementary Figure S1). 
In tunicamycin treated cells, this increase in survival 
reflects reduced induction of apoptosis, as indicated by the 
amount of cleaved PARP protein (Figure 1C). From these 
experiments, we conclude that, at least in this particular 
cell type, loss of BTG1, but not BTG2, enhances cellular 
survival to ATF4-inducing cellular stressors.
BTG1 positively regulates the activity of 
transcription factor ATF4
To examine how the presence or absence of BTG1 
affects cellular stress responses, we performed gene 
expression analyses comparing WT and Btg1−/− MEFs 
subjected to glutamine starvation. We chose glutamine 
deprivation for these analyses since glutamine limitation 
is a physiological stressor known to activate ATF4 and 
frequently encountered by aberrantly proliferating cancer 
cells [46–48]. Using the Ingenuity software package (IPA) 
(see Materials and Methods), we identified transcriptional 
regulators that were either activated or inhibited during 
this nutrient limitation in both WT and Btg1−/− cells 
(Table 1). This analysis confirmed that ATF4 is among 
the top transcription regulators activated by glutamine 
deprivation. We subsequently examined whether 
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ATF4-mediated gene expression was different between 
the two genotypes, by comparing the fold induction of 
ATF4 target genes following glutamine starvation in WT 
versus Btg1 knockout cells. Using predefined criteria 
(see Materials and Methods; fold change (FC) ≥ |3|), we 
identified twelve regulated genes (Table 2). By including 
only genes with established prediction state (activated or 
inhibited), we found that seven out of twelve ATF4 target 
genes, regulated by glutamine limitation, were selectively 
lower expressed in Btg1−/− MEFs (Table 3). We replicated 
and validated these findings by real-time quantitative PCR 
(qPCR) and found that for at least five ATF4 target genes 
(Ddit3, Atf3, Trb3, Ppp1r15a, Ndrg1), upregulation by 
glutamine deprivation was significantly suppressed in Btg1 
knockout cells in comparison to WT cells (Figure 2A). 
Moreover, the attenuated response of these genes was 
specific to the stress treatment, since the expression of 
these genes under non-starved conditions was comparable 
between WT and Btg1−/− cells, except for Ddit3, which 
showed a modest increase in basal expression in the 
knockout setting (data not shown). Importantly, Atf4 mRNA 
induction following glutamine starvation was not 
affected by loss of BTG1 protein expression, suggesting 
that ATF4 activity rather than expression is subject to 
regulation by BTG1 (Figure 2B). For two of these targets 
(Ddit3 and Atf3), we confirmed at the protein level that 
loss of BTG1 protein expression suppresses the extent of 
induction in response to glutamine starvation (Figure 2C). 
To demonstrate that loss of BTG1 reduces the ability 
of ATF4 to activate these target genes, chromatin 
immunoprecipitation (ChIP) assays were performed, 
comparing lysates from primary WT and Btg1−/− MEFs 
Figure 1: BTG1 affects cellular responses to stress. (A) Btg1 mRNA is upregulated in response to various stress stimuli. WT MEFs 
were treated with various stressors and mRNA levels of Btg1 and Btg2 relative to untreated cells are shown. Bars represent average data 
from four independent experiments ± SEM. (B) BTG1, but not BTG2 expression, is required for survival under cellular stress conditions. 
WT, Btg1−/− and Btg2−/− MEFs were challenged with ER stress-inducing drugs (thapsigargin, tunicamycin), glucose depletion, and amino 
acid limitation (glutamine starvation, Asparaginase (ASNase)). Metabolic activity was determined by MTS assay and cell survival relative 
to untreated cells (set at 100%) is shown. Bars represent average data from four independent experiments ± SEM. (C) Loss of BTG1 
protects cells from stress-induced apoptosis. WT and Btg1−/− MEFs were stressed with tunicamycin and apoptosis was measured by western 
blot for cleaved PARP protein. Bars represent average data from three independent experiments ± SEM. P-values are indicated with 
***P < 0.001, **P < 0.01 and *P < 0.05 (two-tailed t-test).
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Table 1: Ingenuity upstream regulator analysis of the transcription factors regulating the expression 
of the genes that we found to be differentially expressed after glutamine starvation in WT and Btg1−/− 
MEFs
WT MEFs
Transcription
regulator Regulated genes
Predicted activation 
state (Z-score)* P-value**
ATF4
Areg, Atf3, Ccl2, Ddit3, Fgf21, Gch1, Lgals3, Mt2a, Ndrg1, 
Nid2, Pmp22, Ppp1r15a, Ptx3, Sars, Slc1a5, Slc6a9, Slc7a3, 
Stc2, Tnfsf11, Trib3
2,509 (activated) 1.00E–14
NUPR1
Adm, Areg, Aspm, Atf3, Atp8b1, Bub1b, C9orf91, Cdca3, 
Cenpi, Ckap2l, Col3a1, Cxadr, Ddit3, Dhcr24, Eno2, Fam83g, 
Gadd45a, Gch1, Gpr1, Gsta4, Hdac8, Hist1h2ag, Hist1h2ah, 
Il13ra1, Kif11, Kif23, Kif2c, Lmnb1, Myh10, Ndrg1, Nupr1, 
Plk1, Pmp22, Ppp1r15a, Spc24, Tmem136, Trib3
4,014 (activated) 4.62E–14
KDM5B
Bub1b, Ccne1, Cdca3, Ddit3, Dhcr24, Dlgap5, Fabp5, 
Gadd45a, Gal, Gjb2, Insig1, Kif2c, Mcam, Ncaph, Nedd9, Pbk, 
Smox, Top2a
4,111 (activated) 1.06E–12
MYC
Acta1, Adm, Anxa6, Aqp1, Birc5, Bub1b, Ccne1, Ccne2, Cd274, 
Cdc20, Chka, Col15a1, Col2a1, Col3a1, Cryab, Ddb2, Ddit3, 
Fabp5, Fads2, Fam129a, Fgf5, Fos, Foxm1, Gadd45a, Gamt, 
H19, Hmox1, Id2, Idh2, Iqgap2, Lum, Lxn, Ndrg1, Peg3, Plau, 
Plk1, Pmp22, Ppp1r15a, Rrm2, Sfrp1, Slc1a5, St3gal1, Thbs1, 
Tnfsf11, Vldlr
–2,607 (inhibited) 2.53E–11
SMAD7 Areg, Ccl2, Ccne1, Col2a1, Col3a1, Fst, Gadd45a, Hmox1, Itgbl1, Ltbp2, Nid2, Sema3f, Tagln, Tgfb2, Tgfb3, Vdr 2,353 (activated) 3.36E–10
Btg1−/− MEFs
Transcription
regulator Regulated genes
Predicted activation 
state (Z-score)* P-value**
NUPR1
Areg, As3mt, Atf3, Aurka, C9orf91, Cdca3, Ckap2l, Cxadr, 
Ddit3, Dhcr24, Espl1, Fam83g, Gadd45a, Gpr1, Hist1h2ag, 
Hist1h2ah, Kif11, Kif23, Kif2c, Lmnb1, Ndrg1, Plk1, Ppp1r15a, 
Spc24, Trib3, Uprt
3,806 (activated) 3.20E–14
KDM5B Aurka, Cdca3, Ddit3, Dhcr24, Dlgap5, Gadd45a, Gjb2, Insig1, Kif2c, Mcam, Ncaph, Pbk, Top2a 3,591 (activated) 9.53E–12
ATF4 Areg, Atf3, Ddit3, Fgf21, Mt2a, Ndrg1, Ppp1r15a, Ptx3, Slc6a9, Stc2, Tnfrsf11a, Tnfsf11, Trib3 2,376 (activated) 1.19E–11
TP53
Areg, Atf3, Aurka, Birc5, Bok, Ccne2, Cdc20, Chst12, Cxcl1, 
Cyp51a1, Ddit3, Dhcr24, Dlgap5, Espl1, Foxm1, Gadd45a, 
Hmox1, Kcnj4, Kif23, Mcam, Melk, Mis18bp1, Ncaph, Ndrg1, 
Pbk, Plau, Plk1, Ppp1r15a, Rad51ap1, Rrm2, Stard4, Top2a, 
Trib3
2,473 (activated) 3.02E–09
CTNNB1
Aoc3, Birc5, Bmp4, Ccne2, Cyp51a1, Eno3, Gjb2, Grem1, 
Kif23, Lck, Mylk, Phlda2, Plau, Plk1, Prss35, Sfrp1, Sqstm1, 
Tgfb3, Tnfsf11, Wnt4
−2,023 (inhibited) 2.38E–08
*Z-score is calculated based on how many times the expression direction of the differentially expressed genes matches 
the expression direction that has been proven to be caused by that transcriptional regulator according to the Ingenuity 
Knowledge Base. It is calculated with a formula reflecting the ‘significant pattern match’ of expression up/down regulation, 
and significance is generally attributed to Z-scores ≥ 2 (‘activated’ transcriptional regulator) or ≤ −2 (‘inhibited’ transcriptional 
regulator).
**This P-value indicates whether there is a statistically significant overlap between the differentially expressed genes and the 
genes of which the expression is known to be regulated by a given transcription factor according to the Ingenuity Knowledge 
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subjected to glutamine starvation. Consistent with a role 
for BTG1 in the regulation of ATF4 activity, we observed a 
decrease in ATF4 binding to the promoter regions of Ddit3 
and Atf3, and to a lesser extent to the promoter of Fgf21, 
in the Btg1−/− MEFs relative to WT controls (Figure 2D). 
Together, these experiments demonstrate that BTG1 
affects cellular responses to stress, by positively regulating 
a subset of ATF4 target genes at the transcriptional level.
ATF4 is a substrate for PRMT1-mediated 
methylation
To further explore how BTG1 controls ATF4 
activity, we performed co-immunoprecipitation (co-IP) 
assays from HEK293 cells made to co-express 
recombinant (FLAG-tagged)-BTG1 and (HA-tagged)-
ATF4, showing that BTG1 complexes with ATF4 
(Figure 3A). Since BTG1 has no known enzymatic 
function, we hypothesized that there may be an additional 
co-factor in the BTG1-ATF4 complex that modulates ATF4 
activity in a BTG1 dependent manner. p300 and pCAF are 
two known activators of ATF4 [49, 50]. By co-IP assays in 
HEK293, we determined whether the interaction between 
ATF4 and either p300 or pCAF was affected upon co-
expression of BTG1, but no differences were observed 
(data not shown). Another candidate cofactor is PRMT1, 
a known binding partner for BTG1 [23, 51]. PRMT1 
Base, which is based on information from the published literature as well as many other sources, including gene expression 
and gene annotation databases (http://www.ingenuity.com). It is calculated with the Fisher’s exact test, and significance is 
generally attributed to P-values < 0.01.
The top five transcription factors that have a predicted activation or inhibition state with a Z-score ≥ |2|are shown
Table 2: ATF4 target genes regulated in response to glutamine starvation in WT and Btg1−/− MEFs
Genes Prediction FC WT FC Btg1−/−
Areg Affected 10,777 6,514
Atf3 Activated 25,831 15,950
Ddit3 Activated 19,262 7,715
Fgf21 Activated 9,716 4,596
Mt2 Affected 9,836 5,096
Ndrg1 Activated 7,593 5,557
Ppp1r15a Activated 7,201 4,689
Ptx3 Activated 4,493 4,489
Slc6a9 Activated 5,943 3,709
Stc2 Affected 5,465 6,912
Tnfsf11 Affected –7,817 –3,804
Trb3 Activated 9,441 6,473
Abbreviations: FC = fold change. Prediction is based on whether the expression of the Atf4 target gene is upregulated or downregulated 
according to the literature (i.e., whether Atf4 is predicted to be activated or inhibited).
Table 3: ATF4 target genes differentially activated under glutamine starvation in WT versus 
Btg1−/− MEFs
Genes FC WT FC Btg1−/−
Atf3 25,831 15,950
Ddit3 19,262 7,715
Fgf21 9,716 4,596
Ndrg1 7,593 5,557
Ppp1r15a 7,201 4,689
Slc6a9 5,943 3,709
Trb3 9,441 6,473
Abbreviations: FC = fold change; Atf3 = Activating transcription factor 3; Ddit3 = DNA damage-inducible transcript 3; Fgf21 = Fibroblast 
growth factor 21; Ndrg1 = N-Myc downstream regulated 1; Ppp1r15a = Protein phosphatase 1, regulatory subunit 15A; Slc6a9 = Solute 
carrier family 6 (neurotransmitter transporter, glycine), member 9; Trb3 = Tribbles pseudokinase 3.
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induces protein arginine methylation, a post-translational 
modification involved in the regulation of transcription 
factor activity [52, 53]. Co-IP assays from primary MEFs 
confirmed that endogenous PRMT1 and ATF4 are in a 
complex, which appears to be dependent on the presence 
of BTG1 (Figure 3B). To complement these findings, we 
re-expressed BTG1 in Btg1−/− MEFs confirming that BTG1 
expression is indispensable for the binding between ATF4 
and PRMT1 (Supplementary Figure S2).
To further analyze if and how BTG1-dependent 
binding of PRMT1 to ATF4 modulates its function, 
we deleted one or more arginine residues present in 
ATF4 to locate potential arginine residue(s) targeted by 
PRMT1-mediated methylation (Figure 3C). We cloned 
ATF4 WT and ATF4 arginine mutants into expression 
plasmids and purified these proteins by their GST tags. 
By in vitro methylation assays combining purified ATF4, 
purified PRMT1 and 35S-adenosylmethionine as a methyl 
donor, we demonstrated that ATF4 is indeed methylated 
by PRMT1 (Figure 3D, top panel). While the deletion 
mutants did not show impaired methylation, we identified 
arginine residue 239 as the most prominent arginine 
Figure 2: Loss of BTG1 negatively affects ATF4-mediated gene expression. (A) Reduced expression of ATF4 target genes in 
Btg1−/− cells upon glutamine depletion. WT and Btg1−/− MEFs were stressed with glutamine starvation for 16 hours and qPCR was performed 
to measure the expression level of the seven ATF4 targets identified by gene expression analysis (Table 3). Data is presented as fold 
induction of mRNA (expression level of untreated samples were set to 1). Bars represent average data from four independent experiments 
± SEM. P-values are indicated with ***P < 0.001, **P < 0.01 and *P < 0.05 (two-tailed paired t-test). (B) The expression level of Atf4 itself 
is not affected by the absence of Btg1. (C) The expression of ATF4 target genes in Btg1−/− cells is also attenuated at protein level. Western 
blot shows the protein expression of two ATF4 targets following glutamine starvation. (D) ATF4 occupancy on target gene promoters is 
affected by loss of BTG1. WT and Btg1−/− MEFs were stressed by glutamine starvation for 16 hours and ChIP was performed using an 
ATF4 antibody to determine ATF4 binding on the promoters of Ddit3, Atf3 and Fgf21. IP without antibody served as negative control. For 
each target gene, qPCR was performed using primers which recognize the ATF4 binding site  (upstream) and a control region around 1.5 kb 
further (downstream). Bars represent average data from three independent experiments ± SEM. P-values are indicated with *P < 0.05 
(two-tailed paired t-test).
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methylated site in ATF4 (Figure 3D, bottom panel). We 
conclude from these experiments that BTG1 promotes 
PRMT1-mediated arginine methylation of ATF4.
PRMT1-mediated methylation potentiates ATF4 
transcriptional activity
To establish if and how ATF4 methylation 
by PRMT1 affects its transcriptional activity, we 
complemented SV40 immortalized Atf4−/− MEFs with 
human wild type ATF4 (ATF4-WT) or methylation mutant 
ATF4-R239K. As a negative control, an empty vector 
was introduced into these Atf4 knockout MEFs. Both 
ATF4-WT and ATF4-R239K were expressed at comparable 
levels as shown by qPCR (Supplementary Figure S3A), 
although expression levels were approximately half 
of that of endogenous ATF4 present in WT cells 
(data not shown). Immunoprecipitations revealed that the 
expression and stability of both proteins was comparable 
(Figure 4A). Subsequently, qPCR was performed in these 
ATF4-complemented MEFs to determine the transcript 
Figure 3: BTG1 facilitates PRMT1 binding to and methylation of ATF4. (A) BTG1 binds to ATF4. HEK293 cells were 
transfected with expression plasmids encoding HA-ATF4 and FLAG-BTG1 and treated for 24 hrs with 5 μM of the proteasome inhibitor 
MG132. Protein lysates were generated and subjected to immunoprecipitation (IP) with FLAG antibody (Ab). Immunoblot demonstrates 
expression of BTG1 using a FLAG-Ab. (B) PRMT1 binds to ATF4 in a BTG1-dependent manner. WT and Btg1−/− MEFs were treated with 
glutamine starvation for 16 h. Protein lysates were generated and subjected to IP with PRMT1 Ab. Immunoblot demonstrates expression of 
ATF4. (C) Mapping of arginine residues found in ATF4. (D) ATF4 is methylated by PRMT1 at amino acid (aa) residue 239. GST-purified 
ATF4 WT and various ATF4 deletion mutants (top panel) and arginine mutants (bottom panel) were subjected to in vitro methylation 
assays together with purified PRMT1 and S-adenosyl methionine as a methyl donor. Proteins were resolved by SDS-PAGE, stained with 
Coomassie blue (ATF4 input), dried and analyzed by autofluorography. Mutation of arginine 239 abolishes methylation of ATF4.
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levels of seven ATF4 target genes listed in Table 3. 
Using this system, complementation of ATF4-WT and 
ATF4-R239K was sufficient to upregulate the expression 
of Trb3, Fgf21 and Slc6a9, but the extent of upregulation 
was significantly reduced for all three target genes 
when the R293K mutant was used (Figure 4B). ATF4 
complementation did not affect target gene regulation 
of the four other ATF4 target genes (Ddit3, Atf3, Ndrg1, 
Ppp1r15a), suggesting that these genes are not exclusively 
dependent on ATF4 function in this immortalized model 
cell line (Supplementary Figure S3B). To further assess 
the contribution of PRMT1-mediated methylation to 
ATF4 function, we inhibited PRMT1 activity with a 
specific molecular inhibitor, AMI-1 [54]. We applied this 
methyl transferase inhibitor to WT MEFs and determined 
by Western blotting that induction of at least two ATF4 
targets, DDIT3 and ATF3, was repressed upon glutamine 
deprivation, while expression of  ATF4 protein remained 
unaffected (Figure 4C). These findings indicate that 
arginine methylation of ATF4 by PRMT1 enhances its 
activity towards a selective set of target genes.
BTG1 and ATF4 are components of the cellular 
stress response in bone marrow-derived B cell 
progenitors
As our results demonstrate that BTG1 and ATF4 are 
important players in cellular stress adaptation in MEFs, 
we speculated that a similar mechanism takes place in 
other cell types. Since BTG1 is frequently deleted in 
B cell progenitor-ALL, we investigated the involvement 
of BTG1 and ATF4 in cellular stress adaptation of CD19 
positive mouse B-cell progenitors isolated from bone 
marrow. Due to unavailability of medium lacking of 
glutamine for growing bone marrow cells, we exposed 
the cells to Asparaginase (ASNase), a cornerstone drug in 
the treatment of ALL patients. ASNase acts by depleting 
asparagine from the blood, causing amino acid limitation 
in lymphocytes as well as leukemic blasts, which are 
uniquely sensitive to this drug as they lack the ability to 
synthesize asparagine. Similar to glutamine starvation, 
ASNase-induced asparagine depletion is known to activate 
ATF4 in an AAR-dependent manner [55]. Consistent with 
Figure 4: Loss of PRMT1-mediated methylation at residue R239 attenuates ATF4 function. (A) Both WT and ATF4-R239K 
are equally expressed. Non-methylated ATF4-R239K was generated by overlap extension PCR (see Materials and Methods). WT and 
ATF4-R239K as well as an empty vector (EV) were retrovirally transduced into immortalized Atf4−/− MEFs. Protein lysates were generated 
and subjected to IP with ATF4Ab. Immunoblot demonstrates expression of ATF4. β-actin levels were used as a loading control. (B) ATF4 
methylation potentiates its activity. EV, ATF4-WT and ATF4-R239K complemented MEFs were subjected to qPCR to determine expression 
of ATF4 targets identified by gene expression analysis (Table 3). Data are presented as fold induction of mRNA (expression level of untreated 
EV MEFs were set to 1). Bars represent average data from four independent experiments ± SEM. P-values are indicated with ***P < 0.001, 
**P < 0.01 and *P < 0.05 (two-tailed paired t-test). (C) WT MEFs were treated with 50 µM AMI-1 in the presence and absence of glutamine 
and western blot was performed for several ATF4 targets. GAPDH levels were used as a loading control.
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a role for BTG1 in modulating ATF4-mediated stress 
responses, we observed that Btg1 mRNA was upregulated 
five-fold by ASNase treatment in these B-cell progenitors 
(Figure 5A). Moreover, we observed similar regulation 
of BTG1 mRNA levels in human peripheral blood 
mononuclear cells (PBMCs) as well as leukemia cell lines 
treated with various stress-inducing agents (Supplementary 
Figure S4). Analogous to what we observed in the MEFs, 
B-cell progenitors derived from Btg1 knockout mice 
showed a 20% increase in survival in comparison to WT 
cells in response to asparagine depletion (Figure 5B). We 
conclude from these experiments that, across different cell 
lineages,  tumor suppressor BTG1 acts as an enhancer of 
ATF4 mediated stress responses, while a loss of BTG1 
function promotes cellular survival in response to nutrient 
stress.
DISCUSSION
BTG1 is one of the genes recurrently affected 
by deletion or mutation in ALL or B-cell lymphoma 
cases, respectively [24, 25, 28, 29]. Furthermore, 
BTG1 mRNA is downregulated in several solid tumors, 
including thyroid, lung, nasopharyngeal and breast 
cancer, while decreased expression is correlated with 
poor overall survival or increased cellular invasion 
[30–34]. While there is ample data to support the notion 
that BTG1 is a negative regulator of proliferation in 
tumor cells [19, 40–42], it remains unclear how BTG1 
deficiency contributes to tumorigenesis. Using primary 
cells (MEFs, progenitor B cells) derived from Btg1−/− 
mice, we demonstrate that loss of Btg1 is sufficient to 
promote adaptation and survival under drug-induced 
ER stress, nutrient starvation and amino acid limitation. 
Although BTG2 is highly similar to BTG1, both in 
structure and function [18], BTG2 expression or regulation 
does not appear to affect the response to these cellular 
stresses in our models. By analyzing gene expression 
in response to glutamine starvation, we identified ATF4 
as the main transcription factor negatively affected by 
loss of BTG1 function. Glutamine is a major source of 
energy and an important metabolite for proliferating cells 
(e.g., fibroblasts, lymphocytes and enterocytes), and in 
addition to glucose metabolism, glutamine consumption 
is frequently elevated in rapidly growing tumor cells 
[46–48, 56]. Glutamine limitation increases ATF4 protein 
translation via the GCN2-eIF2α pathway [14, 15, 57]. 
Intriguingly, we observed that in our experimental model, 
only a subset of ATF4 target genes was dependent on 
BTG1 function. It is known that different subsets of ATF4 
targets are activated in response to different types of stress 
stimuli [3]. Together, our results suggest a unique role for 
BTG1 in regulating the specificity of ATF4 target gene 
activation during nutrient deprivation.
More specifically, our results indicate that BTG1 
dictates ATF4 function and specificity under nutrient 
limiting conditions, by controlling recruitment of ATF4 
to the promoter of its target genes. This regulation is 
most likely achieved through BTG1 interacting with the 
arginine methyl transferase PRMT1. The BTG1-PRMT1 
complex has previously been shown to mediate arginine 
methylation-mediated signaling events as well as 
differentiation [23, 36]. We demonstrate that PRMT1 binds 
to ATF4 in a BTG1-dependent manner and that PRMT1 
methylates ATF4 in vitro. Although arginine 239 is the 
major target for PRMT1 activity, there may be additional 
arginine methylation sites in ATF4, since mutation in this 
residue does not completely abolish methylation of ATF4. 
Experiments using Atf4-deficient MEFs, complemented 
with either recombinant ATF4-WT or the hypo-methylated 
ATF4-R239K, revealed subgroups of ATF4 targets that are 
Figure 5: The absence of Btg1 expression in mouse bone marrow-derived B-cell progenitors enhances cell survival in 
ASNase-treated cells. (A) Btg1 expression is upregulated upon ASNase treatment. WT CD19-positive bone marrow cells were treated 
with 0.5 U/ml ASNase for 48 h. Btg1 mRNA levels were measured by qPCR and the relative expression compared to untreated cells (set to 1) 
is shown. Bars represent average data from four independent experiments ± SEM. (B) WT and Btg1−/− CD19-positive bone marrow cells 
were treated with 0.5 U/ml ASNase for 48 h. The metabolic activity of the cells was measured by MTS assay and the relative cell survival 
compared to untreated cells (set as 100%) is shown. Bars represent average data from six independent experiments ± SEM. p-values are 
indicated with ***P < 0.001 (two-tailed t-test).
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either critically dependent on ATF4 or require a threshold 
level of this transcription factor. In this system, we 
observed such a dependence for three ATF4 target genes 
(Trb3, Fgf21, Slc6a9), and for each of these three genes, 
induction by ATF4 was less prominent in cells expressing 
ATF4-R239K. Similarly, pharmacological inhibition of 
PRMT1 negatively affects protein expression of ATF4 
targets, underscoring an important role for PRMT1 in the 
regulation of stress-mediated gene expression. 
We also established that Btg1 deficiency promotes 
cellular stress adaptation to the protein drug ASNase 
in mouse bone marrow-derived B cell progenitors. 
Importantly, availability of asparagine is sufficient to 
overcome apoptosis induced by glutamine deficiency in 
tumor cells, implying that intracellular asparagine levels 
are critical determinants of the adaptive stress response 
in other malignancies as well [60]. As leukemic blasts 
frequently experience nutrient limitation (as in the 
case of ASNase administration), our findings suggests 
that cells lacking BTG1 may dampen ATF4-mediated 
stress responses, preventing the induction of apoptosis. 
Hence, we hypothesize that loss of BTG1 function, as 
it occurs during leukemic transformation, may provide 
leukemic blasts with a survival advantage, particularly 
when challenged with chemotherapy. Although the 
presence of BTG1 deletions at diagnosis in most patient 
subgroups does not associate with unfavorable prognosis 
in pediatric B-ALL patients [61], the fact that clones 
carrying BTG1 microdeletions are frequently preserved 
and arise de novo at relapse implies that such clones may 
show increased resistance to chemotherapy [26, 27]. 
There is growing evidence that cellular stress response 
pathways are exploited by tumor cells to sustain growth 
under unfavorable conditions or to resist therapy-induced 
apoptosis [62, 63]. Moreover, it was reported recently that 
the UPR arm of the ATF4 signaling cascade plays a key 
role in maintaining the cellular integrity of hematopoietic 
stem cells  exposed to ER stress, by enabling these cells to 
either resolve stress or initiate apoptosis [13].
Although several studies reported upregulation 
of ATF4 to be advantageous for tumor cells under 
unfavorable conditions [14, 38, 64], ATF4-mediated 
survival appears to be determined by both the level 
of ATF4 expression as well as the specificity of 
target genes activated by ATF4 [2, 15]. The fact that 
we see increased survival in Btg1 knockout cells 
under cellular stress conditions, whilst ATF4 activity 
is dampened, should be seen in this context. The 
subset of ATF4 targets affected by Btg1 loss is either 
implicated in the induction of apoptosis or stress-
induced growth arrest. For instance, DDIT3 (C/EBP 
homology protein (CHOP)) and ATF3 are markedly 
upregulated in response to ATF4 activation, particularly 
under prolonged stress conditions, which eventually leads 
to cell death in normal as well as cancer cells [2, 39, 65, 66]. 
Similarly, TRB3 was shown to be responsible for 
neuroblastoma cell death upon glutamine starvation [10, 
15, 65]. PPP1R15A is the mouse homolog of GADD34 
(Growth Arrest and DNA Damage-Inducible 34), 
which is induced by ER stress, nutrient deprivation as 
well as other stress signals, leading to the induction of 
apoptosis [65, 67]. NDRG1 plays a role in stress-induced 
growth arrest and is required for p53-mediated apoptosis 
[68]. Therefore, we postulate that reduced activation 
of these ATF4 target genes, as observed in the Btg1 
knockout cells, improves adaptation to cellular stress by 
avoiding cell death. Overall, our findings identify BTG1 
and PRMT1 as novel determinants of ATF4-mediated 
cellular stress responses (Figure 6). However, it remains 
to be investigated to what extent stress-induced apoptosis 
or salvage mechanisms are affected in tumors that show 
loss of BTG1 function.
Figure 6: Model of BTG1-mediated ATF4 regulation during cellular stress. (A) In response to sustained stress conditions, 
BTG1 recruits PRMT1 to methylate ATF4, - indicated by ‘Me’-  which promotes transcription of a subset of ATF4 target genes, leading  to 
increased apoptosis. (B) In the absence of BTG1, PRMT1 no longer binds to and methylates ATF4, shifting the balance from pro-apoptotic 
to pro-survival. As a consequence, loss of BTG1 function promotes (tumor) cell survival.
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MATERIALS AND METHODS
Cell culture
Generation of C57BL/6J Btg1−/− and Btg2−/− 
mice has been previously reported [20, 69]. Primary 
mouse embryonic fibroblasts (MEFs) were isolated 
by trypsinization of embryos dissected from 
day 13.5 of gestation, and their identities were 
verified by genotyping and quantitative real-time 
PCR (qPCR). SV40-immortalized WT and Atf4−/− 
MEFs were described previously [70]. MEFs 
were cultured in DMEM containing Glutamax 
(Invitrogen) supplemented with 10% heat-inactivated 
fetal bovine serum (FBS; Greiner Bio-One), 1% 
penicillin/streptomycin (P/S; Invitrogen) and 55 µM 
b-mercaptoethanol (Gibco). The medium of immortalized 
MEFs was supplemented with 1% non-essential amino 
acid (Invitrogen). When indicated, glutamine-free 
DMEM (Invitrogen) supplemented with 10% dialyzed 
serum (Invitrogen), P/S and b-mercaptoethanol was 
used. Bone marrow (BM) cells were isolated from 8–12 
week WT and Btg1−/− mice using standard procedures, 
MACS-sorted using CD19 microbeads (Miltenyi Biotec) 
and co-cultured with OP9 stroma in Modified IMEM 
(Invitrogen) supplemented with 2% FBS, 1% P/S, 
b-mercaptoethanol, 0.3% w/v Primatone (Sigma) and 20 
ng/ml IL7 (R&D Systems). The human B-ALL cell line 
(Nalm6) and the HEK293 cell line were purchased from 
ATCC and maintained in RPMI (Invitrogen) and DMEM, 
respectively, supplemented with 10% FBS and 1% P/S. 
Human peripheral blood mononuclear cells (PBMCs) were 
isolated from healthy donors using Ficoll-Paque PLUS 
(GE Healthcare Life Sciences) following manufacturer’s 
protocol and maintained in RPMI supplemented with 10% 
FBS and 1% P/S.
Plasmid construction and transient transfections
pCDNA3-ATF4 was generated by digesting 
pcDNA5/FRT/TO-ATF4-ORF [71] with EcoRI and the 
resulting ATF4 ORF was cloned into pCDNA3.1 using the 
EcoRI sites. FLAG-ATF4 was amplified from pCDNA3. 
1-ATF4 and cloned into XhoI sites of pCDNA3.1. 
HA-BTG1 was amplified by PCR from pLZRS-HA-BTG1 
[36] and cloned into pCDNA3.1 using the EcoRI and XhoI 
sites. Primers used for plasmid construction are listed 
in Supplementary Table S1. For transient transfection 
of HEK293, 5 × 106 cells were seeded in a 10 cm dish 
and transfected with pCDNA3.1-FLAG-ATF4 and 
pCDNA3.1-HA-BTG1 using Polyethylenimine (PEI) 
(Brunschwig Chemie BV). For transient transfection 
of primary MEFs, 2 × 106 cells were seeded in a 10 cm 
dish and transfected with pCDNA3.1-HA-BTG1 or 
empty vector using Viromer Red (Lipocalyx) according 
to manufacturer’s instructions. MG132 proteasome 
inhibitor (Peptides International) was added 24 hours after 
transfection at a final concentration of 5 μM.
Stress induction, cell viability and cellular 
toxicity assay
Human leukemia cell line and MEFs were treated 
with the following conditions: 2 µM thapsigargin (Sigma) 
for 24 h, 2 µg/ml tunicamycin (Sigma) for 24 h, glucose 
starvation (glucose-free DMEM (Invitrogen)) for 48 h, 
glutamine starvation (glutamine-free DMEM) for 24 h, 
and 2 U/ml Asparaginase (Takeda Nederland BV) for 
48 h. CD19-positive B-cell progenitors from the bone 
marrow were treated with 0.5 U/ml Asparaginase for 48 h. 
As much as 5 × 103 MEFs and 2 × 105 bone marrow cells 
were seeded into a 96 well plate and cell viability was 
measured by CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (MTS) reagent (Promega) following 
manufacturer’s protocol. For measurement of cellular 
toxicity, 2 × 104 MEFs were incubated with indicated 
compounds in a 96 well plate and assayed with LDH 
Cytotoxicity Assay following manufacturer’s instruction 
(Thermo Scientific).
mRNA microarray and bioinformatics analysis
Total RNA was extracted from WT and Btg1−/− 
MEFs using RNeasy Minikit (Qiagen) according to 
manufacturer’s protocol. The quality control, RNA 
labeling, hybridization and data extraction were 
performed at ServiceXS B.V. (Leiden, The Netherlands). 
RNA concentration was measured using the Nanodrop 
ND-1000 spectrophotometer (Nanodrop Technologies). 
The RNA quality and integrity were determined using 
Lab-on-Chip analysis on the Agilent 2100 Bioanalyzer 
(Agilent Technologies, Inc.). Biotinylated cRNA was 
prepared using the Illumina TotalPrep RNA Amplification 
Kit (Ambion, Inc.) according to the manufacturer’s 
specifications with an input of 200 ng total RNA. Per 
sample, 750 ng of the obtained biotinylated cRNA samples 
was hybridized onto the Illumina MouseRef-8 v2 (Illumina, 
Inc.). Gene expression data were normalized by the Robust 
Microarray Analysis (RMA) method using ArrayStar® 
software (DNA STAR). To correct for background signals, 
we ruled out the genes with normalized expression below 3. 
Subsequently, the expression value of each gene after 
glutamine starvation was correlated to the expression level 
of the corresponding untreated sample, resulting in a fold 
change (FC) for each gene. We further defined a cut-off of 
≥ |3| for the FC. The genes/mRNAs meeting these criteria 
from both WT and Btg1−/− MEFs were analyzed using 
the Ingenuity Pathway Analysis software package (IPA, 
Ingenuity). For this study, we conducted IPA ‘transcription 
regulator’ analyses of the differentially expressed genes. 
In Table 1, the top five transcription regulators - i.e., the 
regulators with the lowest P values for enrichment of their 
targets within the differentially expressed genes and with 
a clear predicted activation state (Z-score ≥ |2|) - were 
shown. From this list, we generated a list of unique targets, 
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i.e., genes that are differentially expressed in WT 
versus Btg1−/− MEFs following  glutamine starvation 
(Tables 2 and 3).
Quantitative real-time PCR (qPCR)
RNA was isolated as described above. Subsequently, 
1 ug of RNA was used for cDNA synthesis using iScript 
cDNA synthesis kit (Biorad) according to manufacturer’s 
guidelines. cDNA was analyzed by qPCR using SYBR® 
green (Applied Biosystems) on a CFX96™ Real Time 
PCR system (Biorad). Expression levels were normalized 
using the housekeeping gene HPRT (mouse genes) or 
TBP (human genes). Primer sequences used in qPCR 
experiments are listed in Supplementary Table S2.
Co-immunoprecipitation (Co-IP)
MEFs were cultured in DMEM without glutamine 
or in the presence of 2 µg/ml tunicamycin for 24 hours 
to induce ATF4 expression. Cells were collected by 
trypsinization and lysed in RIPA buffer (150 mM NaCl, 
1% NP40, 5 mM EDTA, 50 mM Tris, 0,5% deoxycholate, 
0,1% SDS) supplemented with complete protease 
inhibitor cocktail mix (Roche). For Co-IP, lysates were 
incubated with antibody at 4°C overnight in a turning 
wheel. Subsequently, 25 µl of protein G Sepharose beads 
(GE healthcare) was added to the lysates and incubated 
at 4°C for 1 hour in a turning wheel. Protein-protein 
interactions were determined by immunoblot analysis.
Immunoblot analysis
Cells were lysed in RIPA buffer supplemented with 
complete protease inhibitor cocktail mix. Equal amount of 
proteins were separated by SDS-PAGE and subsequently 
transferred to 0.45 μm PVDF membrane (Thermo 
Scientific). Antibodies used were CHOP (D46F1), ATF-
4 (D4B8), PRMT1 (F339), PARP (#9542) from Cell 
Signaling Technology; CREB-2/ATF4 (C-20), ATF-3 
(C-19), GAPDH (H-12), β-actin (AC-15) from Santa 
Cruz Biotechnology; HA tag (3F10) from Roche; FLAG 
tag (F3165) from Sigma; anti-rabbit and anti-mouse 
HRP from Dako; anti-rabbit IgG light chain HRP 
(ab99697) from Abcam. Protein expression was detected 
by ECL™ Western Blotting Prime Detection Reagent 
(GE Healthcare) and visualized using Fluorochem E 
(Westburg, Cell Biosciences) or autoradiography.
Chromatin Immunoprecipitation (ChIP)
Immunoprecipitated DNA fragments for ChIP 
were prepared from primary WT and Btg1−/− MEFs 
depleted for glutamine  for 16 h, followed by crosslinking 
with 1% formaldehyde for 10 min and ChIP using 
anti-ATF4 (D4B8, Cell Signaling Technology) antibody. 
Immunoprecipitation without an antibody served as 
negative control. For each target gene, qPCR was 
performed using primers that recognize the ATF4 
binding site (upstream) and a control region around 
1.5 kb further (downstream). ChIP-qPCR primers are 
listed in Supplementary Table S3. Promoter occupancy 
was calculated by correcting the percentage recovery of 
each target gene with that of albumin. 
Generation of ATF4 methylation mutants and  
in vitro methylation assay
Deletions of the C-terminus region of ATF4 and 
nucleotide substitutions to convert arginine residues of 
ATF4 into lysine (Figure 3C) were introduced by overlap 
extension PCR using Taq polymerase (Invitrogen) 
following manufacturer’s protocol. The primers used 
for overlap extension PCR are listed in Supplementary 
Table S1. WT and methylation mutants of ATF4 were 
cloned into EcoRI sites of pGEX1N (GE Healthcare Life 
Science). These GST-tagged proteins were produced in 
E. coli BL21 pLysS DE3 Rosetta2 (Millipore) and isolated 
using the B-PER GST spin purification kit (Pierce) 
according to manufacturer’s instruction. As much as 1 μg 
of purified recombinant PRMT1 (ProSpec Bioscience) 
was incubated with 5 μg of purified GST-fusion ATF4 
in the presence of radioactive methyl donor [3H-methyl] 
-S-Adenosyl Methionine (55–85Ci (2.03–3.15TBq)/mM; 
GE Healthcare Life Science) in a total of 30 μl of PBS 
for 2 h at 30°C. The reaction was stopped by addition of 
SDS-PAGE sample buffer and analyzed by SDS-PAGE, 
blotting and autoradiography.
Retroviral transduction
Both WT and R239K ATF4 were cloned into the 
EcoRI sites of pBABE-puro [72]. Retroviruses containing 
WT and R239K ATF4 as well as empty vector (EV) were 
produced in Phoenix ecotropic cells using Lipofectamine 
2000 (Invitrogen) according to manufacturer’s guidelines. 
Immortalized Atf4−/− MEFs were subsequently transduced 
with these three retroviruses and subjected to antibiotic 
selection with 1 ug/ml puromycin (Sigma).
PRMT1 inhibition
PRMT1 methyl transferase activity was inhibited by 
adding AMI-1 (Santa Cruz Biotechnology, sc-205928) at a 
concentration of 50 uM for indicated times, in the absence 
of glutamine.
Statistical analysis
Statistical data are expressed as mean ± SEM. 
Statistical differences were determined with 2-sided, 
paired or unpaired Student’s t tests as indicated in the text; 
p values < 0.001 (***), < 0.01 (**) or < 0.05 (*) were 
considered statistically significant.
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Accession numbers
Illumina bead array expression data have been 
submitted to the NCBI Gene Expression Omnibus 
database (http://www.ncbi.nlm.nih.gov/geo/), accession 
code: GSE63642.
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